<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>429</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15657290</PubmedId>
            <Abstract>The yellow fever vaccine 17D (17D) is safe, and after a single immunizing dose, elicits long-lasting, perhaps lifelong protective immunity. One of the major challenges facing delivery of human vaccines in underdeveloped countries is the need for multiple injections to achieve full efficacy. To examine 17D as a vector for microbial T cell epitopes, we inserted the H-2K(d)-restricted CTL epitope of the circumsporozoite protein (CS) of Plasmodium yoelii between 17D nonstructural proteins NS2B and NS3. The recombinant virus, 17D-Py, was replication competent and stable in vitro and in vivo. A single subcutaneous injection of 10(5) PFU diminished the parasite burden in the liver by approximately 70%. The high level of protection lasted between 4 and 8 wk after immunization, but a significant effect was documented even 24 wk afterwards. Thus, the immunogenicity of a foreign T cell epitope inserted into 17D mimics some of the remarkable properties of the human vaccine. Priming with 17D-Py followed by boosting with irradiated sporozoites conferred sterile immunity to 90% of the mice. This finding indicates that the immune response of vaccine-primed individuals living in endemic areas could be sustained and magnified by the bite of infected mosquitoes.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>201-9</ArticlePages>
            <ArticleTitle>Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Tao</LastName>
                    <ForeName>Deng</ForeName>
                </Author>
                <Author>
                    <LastName>Barba-Spaeth</LastName>
                    <ForeName>Giovanna</ForeName>
                </Author>
                <Author>
                    <LastName>Rai</LastName>
                    <ForeName>Urvashi</ForeName>
                </Author>
                <Author>
                    <LastName>Nussenzweig</LastName>
                    <ForeName>Victor</ForeName>
                </Author>
                <Author>
                    <LastName>Rice</LastName>
                    <ForeName>Charles M</ForeName>
                </Author>
                <Author>
                    <LastName>Nussenzweig</LastName>
                    <ForeName>Ruth S</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Medical and Molecular Parasitology, Department of Pathology, New York University School of Medicine, New York, NY 10016, USA.</Affiliations>
            <ArticleChemicalList>Antigens, Protozoan;Epitopes;Yellow Fever Vaccine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigens, Protozoan(immunology); CD8-Positive T-Lymphocytes(immunology); Epitopes(immunology); Humans; Malaria(immunology; prevention &amp; control); Mice; Plasmodium yoelii(immunology); T-Lymphocytes, Cytotoxic(immunology); Yellow Fever Vaccine(genetics; immunology); Yellow fever virus(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>201</Volume>
                <Issue>2</Issue>
                <Title>The Journal of experimental medicine</Title>
                <Issn>0022-1007</Issn>
                <MedlineTa>J Exp Med</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SYVPSAEQIL</LinearSequence>
                        <StartingPosition>280</StartingPosition>
                        <EndingPosition>289</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P06914.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>5861</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>62752</EpitopeId>
                <ReferenceStartingPosition>280</ReferenceStartingPosition>
                <ReferenceEndingPosition>289</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope is well-known. In this paper, it is presented in different contexts - carried within yellow fever vaccine (17D) and given in different immunization schedules to induce long lasting immunity.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3B</LocationOfData>
                        <TCellId>5197</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Age>6-10 wks</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>124</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SYVPSAEQIL</LinearSequence>
                                            <StartingPosition>280</StartingPosition>
                                            <EndingPosition>289</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06914.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5861</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11089</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>24</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>100000 pfu dose administered weekly for 24 weeks; at the end of immunization mice were challenged with 20000 irradiated sporozoites (P. yoelii), then parasite burden and circumsporozoite-specific CD8+ cells were determined. Other schedules tried are also effective (see Figures  4b, 5b, 6b and 7b).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SYVPSAEQIL</LinearSequence>
                                        <StartingPosition>280</StartingPosition>
                                        <EndingPosition>289</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06914.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5861</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <AssayComments>IFNg-secreting cells were long-lasting, but begin to diminish in number after 16 weeks.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>2505</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Age>6-10 wks</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>124</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SYVPSAEQIL</LinearSequence>
                                            <StartingPosition>280</StartingPosition>
                                            <EndingPosition>289</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06914.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5861</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11089</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>After a single immunization, animals were challenged 2 weeks later with 20000 sporozoites (P. yoelii); after 40-42 h, close to completion of exoerythrocytic stage (EEF), animals were killed, peptide-specific CD8+ cells were determined from the spleen and liver parasite burden was measured. Doses used were: 250, 5000, 100000 and 2000000 pfu; 5 animals were used per dose. Other schedules tried are also effective (see Figures 3a, 4a, 5a, 6a, 7a and Tables 1 and 2).</ImmunizationComments>
                        </Immunization>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Plasmodium yoelii mosquito stage sporozoites</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>5861</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <AssayComments>The highest response (diminished parasite burden) occurred with a 100000 pfu dose while the lowest response was achieved with 250 pfu. Protection was conferred by CD8+ T-cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

